- Biohaven Pharmaceutical (NYSE:BHVN) has started dosing all of the 141 randomized subjects in its Phase 2/3 study assessing trigriluzole (formerly BHV-4157) in spinocerebellar ataxia (SCA), an inherited disorder characterized by degenerative changes in the brain related to movement control.
- Top-line results are expected in Q4, earlier that previously expected.
- Orphan Drug- and Fast Track-tagged trigriluzole is a novel tripeptide prodrug based on the company's glutamate modulator platform.
Biohaven ahead of schedule in clinical trial evaluating trigriluzole in spinocerebellar ataxia, top-line data expected in Q4
Recommended For You
More Trending News
About BHVN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BHVN | - | - |
Biohaven Ltd. |